NCT02258529View on ClinicalTrials.gov

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 14, 2015

Primary Completion Date

April 12, 2016

Study Completion Date

May 3, 2016

Conditions
Follicular LymphomaSmall Lymphocytic Lymphoma
Interventions
DRUG

Idelalisib

150 tablets administered orally twice daily

BIOLOGICAL

Rituximab

375 mg/m\^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)

Trial Locations (6)

21229

St. Agnes Hospital, Baltimore

33916

Florida Cancer Specialists, Fort Myers

37203

Tennessee Oncology, PLLC, Nashville

57201

Prarie Lakes Health Care Systems, Inc., Watertown

90813

Pacific Shores Medical Group, Long Beach

98405

Northwest Medical Specialties, PLLC, Tacoma

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT02258529 - Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter